Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: Risk factors and prognostic significance

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 2055-2058

  Chakrabarti, Suparno ^a   Pillay, Deenan ^a   Ratcliffe, Daina ^a   Cane, Patricia A ^a   Collingham, Kathryn E ^a   Milligan, Donald W ^a,b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; CIPROFLOXACIN; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; PENCICLOVIR;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STEM CELL TRANSPLANTATION; VIRUS ISOLATION;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE; FEMALE; GANCICLOVIR; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034085553     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315524     Document Type: Article

References (15)

1. 1. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes simplex virus infections: a randomized double blind, controlled trial in bone marrow transplant recipients. N Engl J Med 1981; 305:63-7.
2. 2. Hammer SM, Inouye RT. Antiviral agents. In: Richman DD, Whitley RJ, Hayden FG, eds. Clinical virology. New York: Churchill Livingstone, 1997:185-231.
3. 3. Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistance in patients with acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293-6.
4. 4. Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994; 169:193-6.
5. 5. Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 1990; 112:416-22.
6. 6. Nugier F, Colin JN, Aymard M, Langlois M. Occurrence and characterisation of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 1992; 36:1-12.
7. 7. Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983; 148:1077-82.
8. 8. Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990; 162:244-8.
9. 9. Verdonck LF, Cornelissen JJ, Smit J, et al. Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. Bone Marrow Transplant 1993; 11:177-9.
10. 10. Reusser P, Cordonnier C, Einsele H, et al. European survey of herpes virus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:813-7.
11. 11. Darville JM, Ley BE, Roome APCH, Foot ABM. Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population. Bone Marrow Transplant 1998; 22:587-9.
12. 12. LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB. Successful treatment of an acyclovir-and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis 1998; 26:512-3.
13. 13. Schmid DS, Mawle AC. T cell responses to herpes simplex viruses in humans. Rev Infect Dis 1991; 13(Suppl):S946-9.
14. 14. Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant herpes simplex virus mutants. Antiviral Res 1998; 37: 17-28.
15. 15. Mendel DB, Barkheimer DB, Chen MS. Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother 1995; 39:2120-2.